| 1. |
Barglow, K. T. and Cravatt, B. F. (2004) Discovering disease-associated enzymes by proteome reactivity profiling. Chem. Biol.
11, 1523–1531.
|
| |
| 2. |
Hwang, I. K., Park, S. M., Kim, S. Y., and Lee, S.-T. (2004) A proteomic approach to identify substrates of matrix metalloproteinase-14
in human plasma. Biochim. Biophys. Acta
1702, 79–87.
|
| |
| 3. |
Chan, E. W. S., Chattopadhaya, S., Panicker, R. C., Huang, X., and Yao, S. Q. (2004) Developing photoactive affinity probes
for proteomic profiling: hydroxamate-based probes for metalloproteases. J. Am. Chem. Soc.
126, 14, 435–14,446.
|
| |
| 4. |
Saghatelian, A., Jessani, N., Joseph, A., Humphrey, M., and Cravatt, B. F. (2004) Activity-based probes for the proteomic
profiling of metalloproteases. Proc. Natl. Acad. Sci. USA
101, 10,000–10,005.
|
| |
| 5. |
Liu, Y., Patricelli, M. P., and Cravatt, B. F. (1999) Activity-based protein profiling: the serine hydrolases. Proc. Natl. Acad. Sci. USA
96, 14,694–14,699.
|
| |
| 6. |
Sieber, S. A., Mondala, T. S., Head, S. R., and Cravatt, B. F. (2004) Microarray platform for profiling enzyme activities
in complex proteomes. J. Am. Chem. Soc.
126, 15,640–15,641.
|
| |
| 7. |
Greenbaum, D., Medzihradszky, K. F., Burlingame, A., and Bogyo, M. (2000) Epoxide electrophiles as activity-dependent cysteine
protease profiling and discovery tools. Chem. Biol. 7, 569–581.
|
| |
| 8. |
Greenbaum, D., Baruch, A., Hayrapetoan, L., Darula, Z., Burlingame, A., Medzihradszky, K., and Bogyo, M. (2002) Chemical approaches
for functionally probing the proteome. Mol. Cell. Proteomics
1, 60–68.
|
| |
| 9. |
Tam, E. M., Morrison, C. J., Wu, Y. I., Stack, M. S., and Overall, C. M. (2004) Membrane protease proteomics: isotope-coded
affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc. Natl. Acad. Sci. USA
101, 6917–6922.
|
| |
| 10. |
Lopez-Otin, C., and Overall, C. M. (2002) Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell. Biol.
3, 509–519.
|
| |
| 11. |
Baronas-Lowell, D., Lauer-Fields, J. L., and Fields, G. B. (2003) Defining the roles of collagen and collagen-like proteins
within the proteome. J. Liq. Chromatogr. Rel. Technol.
26, 2225–2254.
|
| |
| 12. |
Liotta, L. A. (1992) Cancer cell invasion and metastasis. Scientific American
266(2), 54–63.
|
| |
| 13. |
Birkedal-Hansen, H., Moore, W. G. I., Bodden, et al. (1993) Matrix metalloproteinases: a review, Crit. Rev. Oral Biol. Med.
4, 197–250.
|
| |
| 14. |
Nagase, H. (1996) Matrix metalloproteinases, in Zinc Metalloproteases In Health and Disease (Hooper, N. M., ed.). Taylor & Francis, London: pp. 153–204.
|
| |
| 15. |
Chambers, A. F. and Matrisian, L. M. (1997) Changing views of the role of matrix metalloproteinases in metastasis. J. Nat. Cancer Inst.
89, 1260–1270.
|
| |
| 16. |
Kleiner, D. E. and Stetler-Stevenson, W. G. (1999) Matrix metalloproteinases and metastasis, Cancer Chemother. Pharmacol.
43(Suppl.), S42–S51.
|
| |
| 17. |
Nelson, A. R., Fingleton, B., Rothenberg, M. L., and Matrisian, L. M. (2000) Matrix metalloproteinases: biologic activity
and clinical implications. J. Clin. Oncol.
18, 1135–1149.
|
| |
| 18. |
Chang, C. and Werb, Z. (2001) The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol.
11, S37–S43.
|
| |
| 19. |
Hofmann, U. B., Westphal, J. R., van Muijen, G. N. P., and Ruiter, D. J. (2000) Matrix metalloproteinases in human melanoma.
J. Invest. Dermatol.
115, 337–344.
|
| |
| 20. |
Kajita, M., Itoh, Y., Chiba, T., et al. (2001) Membrane-type 1 matrix metallproteinase cleaves CD44 and promotes cell migration.
J. Cell Biol.
153, 893–904.
|
| |
| 21. |
Mori, H., Tomari, T., Koshifumi, I., et al. (2002) CD44 directs membrane-type I matrix metalloproteinase to lamellipodia by
associating with its hemopexin-like domain. EMBO J.
21, 3949–3959.
|
| |
| 22. |
Ohnishi, Y., Tajima, S., and Ishibashi, A. (2001) Coordinate expression of membrane type-matrix metalloproteinases-2 and 3
(MT2-MMP and MT3-MMP) and matrix metalloproteinase-2 (MMP-2) in primary and metastatic melanoma cells. Eur. J. Dermatol.
11, 420–423.
|
| |
| 23. |
Bodey, B., Bodey, J., B., Siegel, S. E., and Kaiser, H. F. (2001) Matrix metalloproteinase expression in malignant melanomas:
tumor-extracellular matrix interactions in invasion and metastasis. In Vivo
15, 57–64.
|
| |
| 24. |
MacDougall, J. R., Bani, M. R., Lin, Y., Rak, J., and Kerbel, R. S. (1995) The 92-kDa gelatinase B is expressed by advanced
stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells. Cancer Res.
55, 4174–4181.
|
| |
| 25. |
Durko, M., Navab, R., Shibata, H. R., and Brodt, P. (1997) Suppression of basement membrane type IV collagen degradation and
cell invasion in human melanoma cells expressing an antisense RNA for MMP-1. Biochim. Biophys. Acta
1356, 271–280.
|
| |
| 26. |
Lauer-Fields, J. L., Broder, T., Sritharan, T., Nagase, H., and Fields, G. B. (2001) Kinetic analysis of matrix metalloproteinase
triple-helicase activity using fluorogenic substrates. Biochemistry
40, 5795–5803.
|
| |
| 27. |
Fields, G. B. (1991) A model for interstitial collagen catabolism by mammalian collagenases. J. Theor. Biol.
153, 585–602.
|
| |
| 28. |
Billinghurst, R. C., Dahlberg, L., Ionescu, M., et al. (1997) Enhanced cleavage of type II collagen by collagenases in osteoarthritic
articular cartilage. J. Clin. Invest.
99, 1534–1545.
|
| |
| 29. |
Lauer-Fields, J. L., Sritharan, T., Stack, M. S., Nagase, H., and Fields, G. B. (2003) Selective hydrolysis of triple-helical
substrates by matrix metalloproteinase-2 and -9. J. Biol. Chem.
278, 18,140–18,145.
|
| |
| 30. |
Lauer-Fields, J. L., Kele, P., Sui, G., Nagase, H., Leblanc, R. M., and Fields, G. B. (2003) Analysis of matrix metalloproteinase
activity using triple-helical substrates incorporating fluorogenic L- or D-amino acids. Anal. Biochem.
321, 105–115.
|
| |
| 31. |
Minond, D., Lauer-Fields, J. L., Nagase, H., and Fields, G. B. (2004) Matrix metalloproteinase triple-helical peptidase activities
are differentially regulated by substrate stability. Biochemistry
43, 11,474–11,481.
|
| |
| 32. |
Fields, C. G., Mickelson, D. J., Drake, S. L., McCarthy, J. B., and Fields, G. B. (1993) Melanoma cell adhesion and spreading
activities of a synthetic 124-residue triple-helical “mini-collagen”. J. Biol. Chem.
268, 14,153–14,160.
|
| |
| 33. |
Fields, C. G., Lovdahl, C. M., Miles, A. J., Matthias-Hagen, V. L., and Fields, G. B. (1993) Solid-phase synthesis and stability
of triple-helical peptides incorporating native collagen sequences. Biopolymers
33, 1695–1707.
|
| |
| 34. |
Yu, Y.-C., Berndt, P., Tirrell, M., and Fields, G. B. (1996) Self-assembling amphiphiles for construction of protein molecular
architecture. J. Am. Chem. Soc.
118, 12,515–12,520.
|
| |
| 35. |
Yu, Y.-C., Tirrell, M., and Fields, G. B. (1998) Minimal lipidation stabilizes protein-like molecular architecture. J. Am. Chem. Soc.
120, 9979–9987.
|
| |
| 36. |
Corcoran, M. L., Hewitt, R. E., Kleiner, D. E., and Stetler-Stevenson, W. G. (1996) MMP-2: expression, activation and inhibition.
Enzyme Protein
49, 7–19.
|
| |
| 37. |
Giannelli, G., Falk-Marzillier, J., Schiraldi, O., Stetler-Stevenson, W. G., and Quaranta, V. (1997) Induction of cell migration
by matrix metalloprotease-2 cleabage of laminin-5. Science
277, 225–228.
|
| |
| 38. |
Xu, J., Rodriguez, D., Petitclerc, E., et al. (2001) Proteolytic exposure of a cryptic site within collagen type IV is required
for angiogenesis and tumor growth in vivo. J. Cell Biol.
154, 1069–1080.
|
| |
| 39. |
Young, T. N., Pizzo, S. V., and Stack, M. S. (1995) A plasma membrane-associated component of ovarian adenocarcinoma cells
enhances the catalytic efficiency of matrix metalloproteinase-2. J. Biol. Chem.
270, 999–1002.
|
| |
| 40. |
Deryugina, E. I., Bourdon, M. A., Reisfeld, R. A., and Strongin, A. (1998) Remodeling of collagen matrix by human tumor cells
requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res.
58, 3743–3750.
|
| |
| 41. |
Bergers, G., Brekken, R. A., McMahon, G., et al. (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis.
Nature Cell Biol.
2, 737–744.
|
| |
| 42. |
Ramos-DeSimone, N., Hahn-Dantona, E., Sipley, J., Nagase, H., French, D. L., and Quigley, J. P. (1999) Activation of matrix
metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J. Biol. Chem.
274, 13,066–13,076.
|
| |
| 43. |
Fiore, E., Fusco, C., Romero, P., and Stamenkovic, I. (2002) Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically
cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene
21, 5213–5223.
|
| |
| 44. |
Terp, G. E., Cruciani, G., Christensen, I. T., and Jorgensen, F. S. (2002) Structural differences of matrix metalloproteinases
with potential implications for inhibitor selectivity examined by the GRID/CPCA approach. J. Med. Chem.
45, 2675–2684.
|
| |
| 45. |
Mucha, A., Cuniasse, P., Kannan, R., et al. (1998) Membrane type-1 matrix metalloproteinase and stromelysin-3 cleave more
efficiently synthetic substrates containing unusual amino acids in their P
1
’
positions. J. Biol. Chem.
273, 2763–2768.
|
| |
| 46. |
Ohkubo, S., Miyadera, K., Sugimoto, Y., Matsuo, K.-I., Wierzba, K., and Yamada, Y. (1999) Identification of substrate sequences
for membrane type-1 matrix metalloproteinase using bacteriophage peptide display library. Biochem. Biophys. Res. Commun.
266, 308–313.
|
| |
| 47. |
Kridel, S. J., Sawai, H., Ratnikov, B. I., et al. (2002) A unique substrate binding mode discriminates membrane type 1-matrix
metalloproteinase (MT1-MMP) from other matrix metalloproteinases. J. Biol. Chem.
277, 23,788–23,793.
|
| |
| 48. |
Lauer-Fields, J. L., Nagase, H., and Fields, G. B. (2004) Development of a solid-phase assay for analysis of matrix metalloproteinase
activity. J. Biomolecular Techniques
15, 305–316.
|
| |
| 49. |
Kramer, R. H. and Marks, N. (1989) Identification of intracellular collagen receptor on human melanoma cells. J. Biol. Chem.
264, 4684–4688.
|
| |
| 50. |
Miles, A. J., Knutson, J. R., Skubitz, A. P. N., Furcht, L. T., McCarthy, J. B., and Fields, G. B. (1995) A peptide model
of basement membrane collagen α1(IV) 531–543 binds the α3β1 integrin. J. Biol. Chem.
270, 29,047–29,050.
|
| |
| 51. |
Klein, C. E., Dressel, D., Steinmayer, T., et al. (1991) Integrin α2β1 is upregulated in fibroblasts and highly aggressive
melanoma cell in three-dimensional collagen lattices and mediates the reorganization of type I collagen fibrils. J. Cell Biol.
115, 1427–1436.
|
| |
| 52. |
Yoshinaga, I. G., Vink, J., Dekker, S. K., Mihm, M.C., Jr., and Byers, H. R. (1993) Role of α3β1 and α2β1 integrins in melanoma
cell migration, Melanoma Res.
3, 435–441.
|
| |
| 53. |
Heino, J. (1996) Biology of tumor cell invasion: interplay of cell adhesion and matrix degradation. Int. J. Cancer
65, 717–722.
|
| |
| 54. |
Mizejewski, G. J. (1999) Role of integrins in cancer: survey of expression patterns. Proc. Soc. Exp. Biol. Med.
222, 124–138.
|
| |
| 55. |
Etoh, T., Thomas, L., Pastel-Levy, C., Colvin, R. B., Mihm, M. C., Jr., and Byers, H. R. (1993) Role of integrin α2β1 (VLA-2)
in the migration of human melanoma cells on laminin and type IV collagen. J. Invest. Dermatol.
100, 640–647.
|
| |
| 56. |
Knutson, J. R., Iida, J., Fields, G. B., and McCarthy, J. B. (1996) CD44/chondroitin sulfate proteoglycan and α2β1 integrin
mediate human melanoma cell migration on type IV collagen and invasion of basement membranes. Mol. Biol. Cell
7, 383–396.
|
| |
| 57. |
Melchiori, A., Mortarini, R., Carlone, S., et al. (1995) The α3β1 integrin is involved in melanoma cell migration and invasion.
Exp. Cell Res.
219, 233–242.
|
| |
| 58. |
Schön, M., Schön, M. P., Kuhröber, A., Schirmbeck, R., Kaufmann, R., and Klein, C. E. (1996) Expression of the human α2 integrin subunit in mouse melanoma cell confers the ability to undergo collagen-directed adhesion, migration, and matrix
reorganization. J. Invest. Dermatol.
106, 1175–1181.
|
| |
| 59. |
Schwartz, M. A. (2001) Integrin signaling revisited. Trends Cell Biol.
11, 466–470.
|
| |
| 60. |
Hood, J. D. and Cheresh, D. A. (2002) Role of integrins in cell invasion and migration. Nature Rev. Cancer
2, 91–100.
|
| |
| 61. |
Alessandro, R. and Kohn, E. C. (2002) Signal transduction targets in invasion. Clin. Exp. Metastasis
19, 265–273.
|
| |
| 62. |
Riikonen, T., Westermarck, J., Koivisto, L., Broberg, A., Kähäri, V.-M., and Heino, J. (1995) Integrin α2β1 is a positive
regulator of collagenase (MMP-1) and collagen α1(I) gene expression. J. Biol. Chem.
270, 13,548–13,552.
|
| |
| 63. |
Chintala, S. K., Sawaya, R., Gokaslan, Z. L., and Rao, J. S. (1996) Modulation of matrix metalloprotease-2 and invasion in
human glioma cells by α3β1 integrin. Cancer Lett.
103, 201–208.
|
| |
| 64. |
Kubota, S., Ito, H., Ishibashi, Y., and Seyama, Y. (1997) Anti-α3 integrin antibody induces the activated form of matrix metalloprotease-2
(MMP-2) with concomitant stimulation of invasion through matrigel by human rhabdomyosarcoma cells. Int. J. Cancer
70, 106–111.
|
| |
| 65. |
Ellerbroek, S. M., Wu, Y. I., Overall, C. M., and Stack, M. S. (2001) Functional interplay between type I collagen and cell
surface matrix metalloproteinase activity. J. Biol. Chem.
276, 24,833–24,842.
|
| |
| 66. |
Larjava, H., Lyons, J. G., Salo, T., et al. (1993) Anti-integrin antibodies induce type IV collagenase expression in keratinocytes.
J. Cell. Physiol.
157, 190–200.
|
| |
| 67. |
Stricker, T. P., Dumin, J. A., Dickeson, S. K., et al. (2001) Structural analysis of the α2 integrin I domain/procollagenase-1
(matrix metalloproteinase-1) interaction. J. Biol. Chem.
276, 29,375–29,381.
|
| |
| 68. |
Brooks, P. C., Strömblad, S., Sanders, L. C., et al. (1996) Localization of matrix metalloproteinase MMP-2 to the surface
of invasive cells by interaction with integrin αvβ3. Cell
85, 683–693.
|
| |
| 69. |
Miranti, C. K. and Brugge, J. S. (2002) Sensing the environment: a historical perspective on integrin signal transduction.
Nat. Cell Biol.
4, E83–E90.
|
| |
| 70. |
Faassen, A. E., Drake, S. L., Iida, J., Knutson, J. R., and McCarthy, J. B. (1992) Mechanisms of normal cell adhesion to the
extracellular matrix and alterations associated with tumor invasion and metastasis. Adv. Pathol. Lab. Med
5, 229–259.
|
| |
| 71. |
Iida, J., Meijne, A. M. L., Knutson, J. R., Furcht, L. T., and McCarthy, J. B. (1996) Cell surface chondroitin sulfate proteoglycans
in tumor cell adhesion, motility and invasion. Semin. Cancer Biol.
7, 155–162.
|
| |
| 72. |
Leigh, C. J., Palechek, P. L., Knutson, J. R., McCarthy, J. B., Cohen, M. B., and Argenyi, Z. B. (1996) CD44 expression in
benign and malignant nevomelanocytic lesions. Hum. Pathol.
27, 1288–1294.
|
| |
| 73. |
Lesley, J., Hyman, R., English, N., Catterall, J. B., and Turner, G. A. (1997) CD44 in inflammation and metastasis, Glycoconjugate J.
14, 611–622.
|
| |
| 74. |
Ahrens, T., Assmann, V., Fieber, C., et al. (2001) CD44 is the principal mediator of hyaluronic-acid-induced melanoma cell
proliferation, J. Invest. Dermatol.
116, 93–101.
|
| |
| 75. |
Ranuncolo, S. M., Ladeda, V., Gorostidy, S., et al. (2002) Expression of CD44s and CD44 splice variants in human melanoma.
Oncology Reports
9, 51–56.
|
| |
| 76. |
Griffioen, A. W., Coenen, M. J. H., Damen, C. A., et al. (1997) CD44 is involved in tumor angiogenesis; an activation antigen
on human endothelial cells. Blood
90, 1150–1159.
|
| |
| 77. |
Naor, D., Slonov, R. V., and Ish-Shalom, D. (1997) CD44: structure, function, and association with the malignant process,
in Advances in Cancer Research (Vande Woude, G. F., and Klein, G., eds.) Academic, Orlando, FL: pp. 241–319.
|
| |
| 78. |
Eliaz, R. E. and Szoka, F.C., Jr. (2001) Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing
tumor cells, Cancer Res.
61, 2592–2601.
|
| |
| 79. |
Wald, M., Olejár, T., Sebková, V., Zadinová, M., Boubelìk, M., and Poucková, P. (2001) Mixture of trypsin, chymotrypsin and
papain reduces formation of metastases and extends survival time of C57Bl6 mice with syngeneic melanoma B16. Cancer Chemother. Pharmacol.
47, S16–S22.
|
| |
| 80. |
Chelberg, M. K., McCarthy, J. B., Skubitz, A. P. N., Furcht, L. T., and Tsilibary, E. C. (1990) Characterization of a synthetic
peptide from type IV collagen that promotes melanoma cell adhesion, spreading, and motility. J. Cell Biol.
111, 261–270.
|
| |
| 81. |
Mayo, K. H., Parra-Diaz, D., McCarthy, J. B., and Chelberg, M. (1991) Cell adhesion promoting peptide GVKGDKGNPGWPGAP from
the collagen type IV triple helix. Biochemistry
30, 8251–8267.
|
| |
| 82. |
Yu, Y.-C., Pakalns, T., Dori, Y., McCarthy, J. B., Tirrell, M., and Fields, G. B. (1997) Construction of biologically active
protein molecular architecture using self-assembling peptide-amphiphiles. Meth. Enzymol.
289, 571–587.
|
| |
| 83. |
Fields, G. B., Lauer, J. L., Dori, Y., Forns, P., Yu, Y.-C., and Tirrell, M. (1998) Proteinlike molecular architecture: biomaterial
applications for inducing cellular receptor binding and signal transduction. Biopolymers
47, 143–151.
|
| |
| 84. |
Malkar, N. B., Lauer-Fields, J. L., Borgia, J. A., and Fields, G. B. (2002) Modulation of triple-helical stability and subsequent
melanoma cellular responses by single-site substitution of fluoroproline derivatives. Biochemistry
41, 6054–6064.
|
| |
| 85. |
Lauer-Fields, J. L., Malkar, N. B., Richet, G., Drauz, K., and Fields, G. B. (2003) Melanoma cell CD44 interaction with the
α1(IV)1263-1277 region from basement membrane collagen is modulated by ligand glycosylation. J. Biol. Chem.
278, 14,321–14,330.
|
| |
| 86. |
Bourguignon, L. Y. W., Gunja-Smith, Z., Iida, N., et al. (1998) CD44v3,8-10 is involved in cytoskeleton-mediated tumor cell
migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J. Cell. Physiol.
176, 206–215.
|
| |
| 87. |
Yu, Q. and Stamenkovic, I. (1999) Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for
CD44-mediated tumor invasion. Genes Develop.
13, 35–48.
|
| |
| 88. |
Lynch, C. C. and Matrisian, L. M. (2002) Matrix metalloproteinases in tumor-host cell communication. Differentiation
70, 561–573.
|
| |
| 89. |
Carter, W. G. and Wayner, E. A. (1988) Characterization of the class III collagen receptor, a phosphorylated, transmembrane
glycoprotein expressed in nucleated human cells. J. Biol. Chem.
263, 4193–4201.
|
| |
| 90. |
Ehnis, T., Dieterich, W., Bauer, M., von Lampe, B., and Shuppan, D. (1996) A chondroitin/dermatan sulfate form of CD44 is
a receptor for collagen XIV (undulin). Exp. Cell Res.
229, 388–397.
|
| |
| 91. |
Faassen, A. E., Schrager, J. A., Klein, D. J., Oegema, T. R., Couchman, J. R., and McCarthy, J. B. (1992) A cell surface chondroitin
sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and
invasion. J. Cell Biol.
116, 521–531.
|
| |
| 92. |
Fujisaki, T., Tanaka, Y., Fujii, K., et al. (1999) CD44 stimulation induces integrin-mediated adhesion of colon cancer cell
lines to endothelial cells by up-regulation of integrins and c-Met activation of integrins. Cancer Res.
59, 4427–4434.
 |